Screener
Crinetics Pharmaceuticals CRNX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
FAQ
- What is Crinetics Pharmaceuticals's EPS (diluted)?
- Crinetics Pharmaceuticals (CRNX) reported EPS (diluted) of -$1.23 in Q1 2026.
- How has Crinetics Pharmaceuticals's EPS (diluted) changed year-over-year?
- Crinetics Pharmaceuticals's EPS (diluted) decreased by 18.3% year-over-year, from -$1.04 to -$1.23.
- What is the long-term trend for Crinetics Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EPS (diluted) has grown at a 15.4% compound annual growth rate (CAGR), from -$2.79 to -$4.94.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Crinetics Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude